Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Azar And The Return Of Republican-Style Price Negotiation

Executive Summary

The nomination of a former drug industry executive to run HHS is obviously good news for the biopharma sector, but it does not mean that HHS will do nothing about drug prices. On the contrary, it may make some high-profile action against pricing outliers all but inevitable.

Advertisement

Related Content

Trump Expecting Rx Price Reduction Announcements In Two Weeks
The Spectacle Of Trump: Tweets, Insults And A Year Pharma Won't Forget
HHS Nominee Azar And The Taint Of Industry
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel